{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:04:51Z","timestamp":1786993491088,"version":"build-2736575974"},"reference-count":44,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.jtct.2025.11.034","type":"journal-article","created":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T00:46:06Z","timestamp":1764809166000},"page":"320-336","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Low-Dose Post-Transplant Cyclophosphamide in Haploidentical Stem Cell Transplantation: A Systematic Review"],"prefix":"10.1016","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1202-7214","authenticated-orcid":false,"given":"Areez","family":"Shafqat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed H.","family":"Omer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7617-3678","authenticated-orcid":false,"given":"Shameel","family":"Shafqat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulrahman","family":"Nasiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Kotb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1939-1665","authenticated-orcid":false,"given":"Ali","family":"Mushtaq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2096-2357","authenticated-orcid":false,"given":"Mary Pat","family":"Harnegie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Alahmari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed O.","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2872-2203","authenticated-orcid":false,"given":"Walid","family":"Rasheed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hazzaa","family":"Alzahrani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahrukh","family":"Hashmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayman","family":"Saad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud","family":"Aljurf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4498-3865","authenticated-orcid":false,"given":"Riad","family":"El-Fakih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mostafa F. Mohammed","family":"Saleh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jtct.2025.11.034_bib0001","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1182\/asheducation.V2012.1.230.3798312","article-title":"Haploidentical transplantation for hematologic malignancies: where do we stand?","volume":"2012","author":"Fuchs","year":"2012","journal-title":"Hematology"},{"issue":"6","key":"10.1016\/j.jtct.2025.11.034_bib0002","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.bbmt.2008.03.005","article-title":"HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide","volume":"14","author":"Luznik","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"10.1016\/j.jtct.2025.11.034_bib0003","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/sj.bmt.1705445","article-title":"Haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion for the treatment of hematological malignancies","volume":"38","author":"Huang","year":"2006","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2025.11.034_bib0004","doi-asserted-by":"crossref","DOI":"10.7759\/cureus.59744","article-title":"Real-world challenges of haplo-identical hematopoietic stem cell transplant in a developing country: a single center experience","author":"Akram","year":"2024","journal-title":"Cureus"},{"issue":"3","key":"10.1016\/j.jtct.2025.11.034_bib0005","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.hemonc.2020.07.008","article-title":"Hematopoietic stem cell transplantation in Saudi Arabia between 1984 and 2016","volume":"14","author":"Shaheen","year":"2021","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"10.1016\/j.jtct.2025.11.034_bib0006","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"10","key":"10.1016\/j.jtct.2025.11.034_bib0007","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1182\/bloodadvances.2024014879","article-title":"Intermediate-dose posttransplantation cyclophosphamide for myeloablative HLA-haploidentical bone marrow transplantation","volume":"9","author":"Hyder","year":"2025","journal-title":"Blood Adv"},{"issue":"3","key":"10.1016\/j.jtct.2025.11.034_bib0008","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1038\/s41409-020-01065-0","article-title":"Reduced dose of posttransplant cyclophosphamide in HLA-haploidentical peripheral blood stem cell transplantation","volume":"56","author":"Sugita","year":"2020","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"10.1016\/j.jtct.2025.11.034_bib0009","doi-asserted-by":"crossref","first-page":"754","DOI":"10.3109\/08880018.2014.961214","article-title":"Feasibility of HLA-haploidentical hematopoietic stem cell transplantation with post-transplantation cyclophosphamide for advanced pediatric malignancies","volume":"31","author":"Sawada","year":"2014","journal-title":"Pediatr Hematol Oncol"},{"key":"10.1016\/j.jtct.2025.11.034_bib0010","doi-asserted-by":"crossref","DOI":"10.1177\/09636897221079739","article-title":"Lower absolute lymphocyte count before conditioning predicts high relapse risk in patients after haploidentical peripheral blood stem cell transplantation with low dose anti-thymocyte globulin\/post-transplant cyclophosphamide for GvHD prophylaxis","volume":"31","author":"Zhou","year":"2022","journal-title":"Cell Transplant"},{"issue":"7","key":"10.1016\/j.jtct.2025.11.034_bib0011","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1038\/s41409-018-0382-3","volume":"54","author":"Yang","year":"2018","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2025.11.034_bib0012","article-title":"Low-dose anti-thymocyte globulin plus low-dose post-transplant cyclophosphamide-based regimen for prevention of graft-versus-host disease after haploidentical peripheral blood stem cell transplants: a large sample, long-term follow-up retrospective study","volume":"14","author":"Li","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.jtct.2025.11.034_bib0013","first-page":"31","article-title":"A prospective study of an HLA-haploidentical peripheral blood stem cell transplantation regimen based on modification of the dose of posttransplant cyclophosphamide for poor prognosis or refractory hematological malignancies","author":"Nakamae","year":"2022","journal-title":"Cell Transplant"},{"key":"10.1016\/j.jtct.2025.11.034_bib0014","article-title":"Low-dose post-transplant cyclophosphamide with G-CSF\/ATG based haploidentical protocol provides favorable outcomes for SAA patients","volume":"14","author":"Ma","year":"2023","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.jtct.2025.11.034_bib0015","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/j.1445-5994.2012.02843.x","article-title":"Haploidentical bone marrow transplants for haematological malignancies using non-myeloablative conditioning therapy and post-transplant immunosuppression with cyclophosphamide: results from a single Australian centre","volume":"43","author":"Bilmon","year":"2013","journal-title":"Intern Med J"},{"issue":"4","key":"10.1016\/j.jtct.2025.11.034_bib0016","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1038\/bmt.2016.301","article-title":"Dose-adapted post-transplant cyclophosphamide for HLA-haploidentical transplantation in Fanconi anemia","volume":"52","author":"Thakar","year":"2017","journal-title":"Bone Marrow Transplant"},{"issue":"12","key":"10.1016\/j.jtct.2025.11.034_bib0017","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1016\/j.bbmt.2020.08.019","article-title":"Haploidentical stem cell transplantation with post-transplant cyclophosphamide in fanconi anemia: improving outcomes with improved supportive care in India","volume":"26","author":"Uppuluri","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"10.1016\/j.jtct.2025.11.034_bib0018","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1007\/s00277-025-06305-1","volume":"104","author":"Jia","year":"2025","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jtct.2025.11.034_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2025.107721","article-title":"Parous female donor is not inferior to the young male donor under the low-dose ATG\/PTCy combination-based regimen for GVHD prophylaxis in haploidentical peripheral blood stem cell transplantation","volume":"154","author":"Li","year":"2025","journal-title":"Leuk Res"},{"issue":"8","key":"10.1016\/j.jtct.2025.11.034_bib0020","doi-asserted-by":"crossref","first-page":"3135","DOI":"10.1007\/s00277-024-05818-5","article-title":"Reduced-toxicity conditioning regimen with low dose post-transplantation cyclophosphamide and low-dose anti-thymocyte globulin as graft-versus-host disease prophylaxis for haploidentical stem cell transplantation in older patients","volume":"103","author":"Ye","year":"2024","journal-title":"Ann Hematol"},{"issue":"2","key":"10.1016\/j.jtct.2025.11.034_bib0021","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/bjh.18483","volume":"200","author":"Zhang","year":"2022","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.jtct.2025.11.034_bib0022","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1111\/bjh.19228","article-title":"Low- versus standard-dose post-transplant cyclophosphamide as GVHDprophylaxis for haploidentical transplantation","volume":"204","author":"Fuji","year":"2023","journal-title":"Br J Haematol"},{"issue":"11","key":"10.1016\/j.jtct.2025.11.034_bib0023","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1038\/s41409-023-02085-2","article-title":"Reduced post-transplant cyclophosphamide dose with antithymocyte globulin in peripheral blood stem cell haploidentical transplantation","volume":"58","author":"Dul\u00e9ry","year":"2023","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"10.1016\/j.jtct.2025.11.034_bib0024","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/s41409-022-01908-y","article-title":"Reduced post-transplant cyclophosphamide doses in haploidentical hematopoietic cell transplantation for elderly patients with hematological malignancies","volume":"58","author":"Dul\u00e9ry","year":"2022","journal-title":"Bone Marrow Transplant"},{"issue":"12","key":"10.1016\/j.jtct.2025.11.034_bib0025","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1111\/tri.13494","article-title":"A prospective observational study of immune reconstitution following transplantation with post-transplant reduced-dose cyclophosphamide from HLA-haploidentical donors","volume":"32","author":"Nakamae","year":"2019","journal-title":"Transplant Internat"},{"issue":"1","key":"10.1016\/j.jtct.2025.11.034_bib0026","volume":"71","author":"Cao","year":"2023","journal-title":"Curr Res Transl Med"},{"issue":"1","key":"10.1016\/j.jtct.2025.11.034_bib0027","article-title":"Dual T-cell depletion with individually tailored anti-thymocyte globulin and attenuated dose of post-transplant cyclophosphamide in haploidentical peripheral stem cell transplantation","volume":"14","author":"Kim","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.jtct.2025.11.034_bib0028","doi-asserted-by":"crossref","DOI":"10.1177\/09636897221139103","article-title":"Low-dose anti-thymocyte globulin plus low-dose posttransplant cyclophosphamide as an effective regimen for prophylaxis of graft versus host disease after haploidentical peripheral blood stem cell transplantation with maternal\/collateral related donors","volume":"31","author":"Li","year":"2022","journal-title":"Cell Transplant"},{"issue":"3","key":"10.1016\/j.jtct.2025.11.034_bib0029","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1038\/s41409-020-01047-2","volume":"56","author":"Xu","year":"2020","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"10.1016\/j.jtct.2025.11.034_bib0030","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1007\/s12185-022-03405-w","article-title":"Outcomes of salvage haploidentical transplantation using posttransplant cyclophosphamide for graft failure following allogeneic hematopoietic stem cell transplantation","volume":"116","author":"Harada","year":"2022","journal-title":"Int J Hematol"},{"key":"10.1016\/j.jtct.2025.11.034_bib0031","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.921293","article-title":"Modified combination of anti-thymocyte globulin (ATG) and post-transplant cyclophosphamide (PTCy) as compared with standard ATG protocol in haploidentical peripheral blood stem cell transplantation for acute leukemia","volume":"13","author":"Barkhordar","year":"2022","journal-title":"Front Immunol"},{"issue":"11","key":"10.1016\/j.jtct.2025.11.034_bib0032","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/j.exphem.2015.07.006","article-title":"HLA haploidentical peripheral blood stem cell transplantation using reduced dose of posttransplantation cyclophosphamide for poor-prognosis or refractory leukemia and myelodysplastic syndrome","volume":"43","author":"Nakamae","year":"2015","journal-title":"Exp Hematol"},{"issue":"Supplement 1","key":"10.1016\/j.jtct.2025.11.034_bib0033","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1182\/blood-2023-181489","article-title":"The doses of post-transplantation cyclophosphamide in haploidentical stem cell allografts can be reduced","volume":"142","author":"Olivares-Gazca","year":"2023","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.jtct.2025.11.034_bib0034","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1002\/jha2.962","article-title":"Combination of reduced post-transplant cyclophosphamide and early tacrolimus initiation increases the incidence of chronic graft-versus-host disease in human leukocyte antigen-haploidentical peripheral blood stem-cell transplantation","volume":"5","author":"Terao","year":"2024","journal-title":"EJHaem"},{"issue":"1","key":"10.1016\/j.jtct.2025.11.034_bib0035","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-80531-7","article-title":"Feasibility of reduced-dose posttransplant cyclophosphamide and cotransplantation of peripheral blood stem cells and umbilical cord-derived mesenchymal stem cells for SAA","volume":"11","author":"Zu","year":"2021","journal-title":"Sci Rep"},{"issue":"11","key":"10.1016\/j.jtct.2025.11.034_bib0036","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1356152","article-title":"Low-dose post-transplant cyclophosphamide can mitigate GVHD and enhance the G-CSF\/ATG induced GVHD protective activity and improve haploidentical transplant outcomes","volume":"6","author":"Wang","year":"2017","journal-title":"Oncoimmunology"},{"issue":"1","key":"10.1016\/j.jtct.2025.11.034_bib0037","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-019-0781-y","article-title":"Low-dose post-transplant cyclophosphamide and anti-thymocyte globulin as an effective strategy for GVHD prevention in haploidentical patients","volume":"12","author":"Wang","year":"2019","journal-title":"J Hematol Oncol"},{"issue":"7","key":"10.1016\/j.jtct.2025.11.034_bib0038","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1038\/s41409-024-02277-4","article-title":"Post-transplant cyclophosphamide at 80\u2009mg\/kg with low dose post-engraftment anti-thymocyte globulin in haploidentical transplantation with myeloablative conditioning","volume":"59","author":"Wang","year":"2024","journal-title":"Bone Marrow Transplant"},{"issue":"12","key":"10.1016\/j.jtct.2025.11.034_bib0039","first-page":"2965","article-title":"Randomized trial of anti-thymocyte globulin plus low-dose post-transplant cyclophosphamide to prevent graft-versus-host disease in haploidentical transplantation","volume":"110","author":"Xu","year":"2025","journal-title":"Haematologica"},{"issue":"7","key":"10.1016\/j.jtct.2025.11.034_bib0040","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1038\/s41409-024-02277-4","article-title":"Post-transplant cyclophosphamide at 80\u2009mg\/kg with low dose post-engraftment anti-thymocyte globulin in haploidentical transplantation with myeloablative conditioning","volume":"59","author":"Wang","year":"2024","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"10.1016\/j.jtct.2025.11.034_bib0041","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1007\/s00277-025-06305-1","volume":"104","author":"Jia","year":"2025","journal-title":"Ann Hematol"},{"issue":"2","key":"10.1016\/j.jtct.2025.11.034_bib0042","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1038\/bmt.2015.93","article-title":"Unmanipulated haploidentical bone marrow transplantation and post-transplant cyclophosphamide for hematologic malignanices following a myeloablative conditioning: an update","volume":"50","author":"Bacigalupo","year":"2015","journal-title":"Bone Marrow Transplant"},{"issue":"18","key":"10.1016\/j.jtct.2025.11.034_bib0043","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1002\/cncr.35365","volume":"130","author":"Bazarbachi","year":"2024","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.jtct.2025.11.034_bib0044","first-page":"629","article-title":"Clinical outcomes of three haploidentical transplantation protocols for hematologic malignancies based on data from the Chinese Bone Marrow Transplantation Registry Group","volume":"110","author":"Xu","year":"2025","journal-title":"Haematologica"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636725016112?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636725016112?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T05:40:15Z","timestamp":1773985215000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636725016112"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":44,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S2666636725016112"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2025.11.034","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Low-Dose Post-Transplant Cyclophosphamide in Haploidentical Stem Cell Transplantation: A Systematic Review","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2025.11.034","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Society for Transplantation and Cellular Therapy. Published by Elsevier, Inc.","name":"copyright","label":"Copyright"}]}}